Trial Search Results

Estrogen Use in Protection From Cognitive Decline

This study is designed to assess the effects of estrogen therapy among postmenopausal women at risk for cognitive decline.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: National Institute on Aging (NIA)

Stanford Investigator(s):


Inclusion Criteria:

   - Women between the ages of 45 and 65

   - Currently on hormone replacement

   - One year or more post complete cessation of menses

   - Willing to sign the Human Subject Protection Consent form prior to enrollment in the

   - Willing to be randomized to continue or discontinue estrogen therapy

   - Adequately visually and auditorially acute to allow neuropsychological testing

   - Beyond 8 years of educational achievement to allow adequate neuropsychological testing

   - Willing to undergo brain imaging

   - At risk for cognitive decline, as defined by one or more of the following: Personal or
   family history of mood disorder, Hypothyroidism, Diabetes, Family history of
   Alzheimer's, APOE-4 allele

Exclusion Criteria:

   - Diagnosis of possible or probable Alzheimer's disease or dementia

   - Cerebrovascular disease or uncontrolled hypertension (systolic BP >170 or diastolic BP

   - History of myocardial infarction within previous year or unstable heart disease

   - History of significant liver disease, pulmonary disease, or current cancer

   - Contraindication for MRI (metal in body, claustrophobia, etc.)

Ages Eligible for Study

45 Years - 65 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305